Puma Biotechnology
PBYI
116 hedge funds and large institutions have $90M invested in Puma Biotechnology in 2025 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 44 increasing their positions, 25 reducing their positions, and 20 closing their positions.
1,680% more call options, than puts
Call options by funds: $178K | Put options by funds: $10K
76% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 25
20% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 20
4% more funds holding
Funds holding: 112 → 116 (+4)
1.43% more ownership
Funds ownership: 59.88% → 61.31% (+1.4%)
0% more capital invested
Capital invested by funds: $89.7M → $90M (+$370K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$1.12M |
| 2 |
D.E. Shaw & Co
New York
|
+$1.09M |
| 3 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$1.08M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
+$632K |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$630K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
-$2.25M |
| 2 |
Millennium Management
New York
|
-$1.59M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$499K |
| 4 |
JP Morgan Chase
New York
|
-$277K |
| 5 |
Squarepoint
New York
|
-$232K |
PBYI Hedge Fund Activity: Q1 2025 in Review
116 of the 7,471 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q1 2025, worth a combined $90M — up 0.41% from $89.7M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new PBYI positions and 20 closed out — a net gain of 4 holders — while 44 added to existing stakes and 25 trimmed.
The largest buyer was Arrowstreet Capital, opening a new position worth an estimated $1.12M. The largest seller was Eversept Partners, cutting an estimated $2.25M.
- 116 institutional investors held Puma Biotechnology (PBYI) as of Q1 2025, up from 112 in Q4 2024.
- Funds reported $90M of Puma Biotechnology stock for Q1 2025, up 0.41% quarter-over-quarter.
- 24 funds opened new Puma Biotechnology positions in Q1 2025 and 20 closed out, a net change of +4 holders.
- The largest Puma Biotechnology buyer in Q1 2025 was Arrowstreet Capital, an estimated $1.12M added.
- The largest Puma Biotechnology seller in Q1 2025 was Eversept Partners, an estimated $2.25M sold.
Based on aggregated 13F filings for Q1 2025.